Published in Acta Neuropathol Commun on January 21, 2015
Isocitrate dehydrogenase mutations in gliomas. Neuro Oncol (2015) 0.93
Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas. Metabolites (2017) 0.82
IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro Oncol (2016) 0.80
Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol (2017) 0.77
Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology (2016) 0.76
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. J Blood Med (2016) 0.76
IGFBP2 expression predicts IDH-mutant glioma patient survival. Oncotarget (2016) 0.75
Immunotherapy in glioblastoma: emerging options in precision medicine. CNS Oncol (2016) 0.75
Single vs. combination immunotherapeutic strategies for glioma. Expert Opin Biol Ther (2017) 0.75
EGFR Amplification and IDH Mutations in Glioblastoma Patients of the Northeast of Morocco. Biomed Res Int (2017) 0.75
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med (1993) 15.51
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science (2009) 10.78
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
The central role of CD4(+) T cells in the antitumor immune response. J Exp Med (1998) 6.02
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science (2013) 4.88
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature (2012) 4.37
A vaccine targeting mutant IDH1 induces antitumour immunity. Nature (2014) 3.90
The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol (1998) 3.68
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature (2014) 2.77
Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med (1998) 2.72
D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev (2012) 2.10
Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol (2002) 1.93
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest (2013) 1.89
Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci (2006) 1.74
Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med (2007) 1.64
Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma. Proc Natl Acad Sci U S A (2014) 1.62
CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol (2007) 1.54
Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol (2010) 1.43
What do we know about IDH1/2 mutations so far, and how do we use it? Acta Neuropathol (2013) 1.36
Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res (2009) 1.27
Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif. J Immunol (1993) 1.24
A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J Immunol (1999) 1.22
R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma. Acta Neuropathol (2010) 1.22
New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov (2013) 1.22
WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother (2010) 1.20
Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int J Cancer (2010) 1.11
Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. J Exp Med (2013) 1.08
Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma. J Mol Med (Berl) (2012) 1.08
Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma. Cancer Res (2014) 1.00
Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma. Br J Cancer (2014) 1.00
Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am J Clin Oncol (2006) 0.97
IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. Future Oncol (2013) 0.95
Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists. Vaccine (2006) 0.92
Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. Neuro Oncol (2012) 0.90
Detection of IDH1 mutation in the plasma of patients with glioma. Neurology (2012) 0.87
Immunotherapy against the radial glia marker GLAST effectively triggers specific antitumor effectors without autoimmunity. Oncoimmunology (2012) 0.83
Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy. Acta Neuropathol Commun (2014) 0.83
Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response. PLoS One (2014) 0.79
Cramér-Rao bounds on mensuration errors. Appl Opt (1976) 0.77
Tumor size and karyometric variables in brain astrocytoma. J BUON (2009) 0.77
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 5.09
Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A (2010) 4.35
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol (2008) 2.18
Conversion of the BASE prion strain into the BSE strain: the origin of BSE? PLoS Pathog (2007) 1.97
Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry (2010) 1.94
Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol (2006) 1.92
Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res (2006) 1.89
Is fluorescein-guided technique able to help in resection of high-grade gliomas? Neurosurg Focus (2014) 1.74
Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat Chem Biol (2013) 1.65
Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol (2007) 1.59
Age-related iron deposition in the basal ganglia: quantitative analysis in healthy subjects. Radiology (2009) 1.56
Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas. Cancer Biol Ther (2006) 1.54
High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol Cancer Res (2009) 1.53
Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Res (2010) 1.48
Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res (2007) 1.42
Cross platform microarray analysis for robust identification of differentially expressed genes. BMC Bioinformatics (2007) 1.39
Fluorescein-guided surgery for grade IV gliomas with a dedicated filter on the surgical microscope: preliminary results in 12 cases. Acta Neurochir (Wien) (2013) 1.34
The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res (2012) 1.21
Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res (2007) 1.19
New insights into brain damage in stroke-prone rats: a nuclear magnetic imaging study. Stroke (2002) 1.18
PoInTree: a polar and interactive phylogenetic tree. Genomics Proteomics Bioinformatics (2005) 1.18
A role for the transcription factor HEY1 in glioblastoma. J Cell Mol Med (2008) 1.16
NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget (2012) 1.15
Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment. Neuro Oncol (2010) 1.13
Current concepts in Alzheimer's disease: a multidisciplinary review. Am J Alzheimers Dis Other Demen (2009) 1.12
Chronic migraine with medication overuse pre-post withdrawal of symptomatic medication: clinical results and FMRI correlations. Headache (2010) 1.12
NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther (2012) 1.10
Expression of the neurogenic basic helix-loop-helix transcription factor NEUROG1 identifies a subgroup of medulloblastomas not expressing ATOH1. Neuro Oncol (2007) 1.10
The therapeutic potential of neural stem/progenitor cells in murine globoid cell leukodystrophy is conditioned by macrophage/microglia activation. Neurobiol Dis (2005) 1.08
CXCL12, CXCR4 and CXCR7 expression in brain metastases. Cancer Biol Ther (2009) 1.08
Neuroradiological diagnosis of Chiari malformations. Neurol Sci (2011) 1.07
Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma. Mol Cancer (2004) 1.06
Neuritis ossificans. J Neurosurg (2014) 1.06
Searching for biomarkers of Aurora-A kinase activity: identification of in vitro substrates through a modified KESTREL approach. J Proteome Res (2005) 1.06
Expression of MATH1, a marker of cerebellar granule cell progenitors, identifies different medulloblastoma sub-types. Neurosci Lett (2004) 1.05
Analysis of pathological events at the onset of brain damage in stroke-prone rats: a proteomics and magnetic resonance imaging approach. J Neurosci Res (2004) 1.03
Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol (2008) 1.02
Alkylsulfanyl-1,2,4-triazoles, a new class of allosteric valosine containing protein inhibitors. Synthesis and structure-activity relationships. J Med Chem (2013) 1.02
Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels. J Neurooncol (2009) 1.02
Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships. J Med Chem (2008) 1.01
Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma. Cancer Res (2014) 1.00
Functional MRI/event-related potential study of sensory consonance and dissonance in musicians and nonmusicians. Neuroreport (2009) 1.00
Different simian virus 40 genomic regions and sequences homologous with SV40 large T antigen in DNA of human brain and bone tumors and of leukocytes from blood donors. Cancer (2002) 1.00
Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010. Neuro Oncol (2014) 0.99
Interaction between ephrins/Eph receptors and excitatory amino acid receptors: possible relevance in the regulation of synaptic plasticity and in the pathophysiology of neuronal degeneration. J Neurochem (2006) 0.98
Quantitation of normal metabolite concentrations in six brain regions by in-vivoH-MR spectroscopy. J Med Phys (2010) 0.97
Substantia nigra in Parkinson's disease: a multimodal MRI comparison between early and advanced stages of the disease. Neurol Sci (2013) 0.97
Nestin, PDGFRbeta, CXCL12 and VEGF in glioma patients: different profiles of (pro-angiogenic) molecule expression are related with tumor grade and may provide prognostic information. Cancer Biol Ther (2007) 0.97
CXCL12 in malignant glial tumors: a possible role in angiogenesis and cross-talk between endothelial and tumoral cells. J Neurooncol (2004) 0.97
A new approach to phosphoserine and phosphothreonine analysis in peptides and proteins: chemical modification, enrichment via solid-phase reversible binding, and analysis by mass spectrometry. Anal Bioanal Chem (2003) 0.97
Rescue of ATPa3-deficient murine malignant osteopetrosis by hematopoietic stem cell transplantation in utero. Proc Natl Acad Sci U S A (2005) 0.96
Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study. Int J Radiat Oncol Biol Phys (2004) 0.95
Hind limb muscle atrophy precedes cerebral neuronal degeneration in G93A-SOD1 mouse model of amyotrophic lateral sclerosis: a longitudinal MRI study. Exp Neurol (2011) 0.94
Epilepsy in cerebral glioma: timing of appearance and histological correlations. J Neurooncol (2009) 0.94
Expression of the new CXCL12 receptor, CXCR7, in gliomas. Cancer Biol Ther (2011) 0.93
The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. Int J Biol Markers (2009) 0.93
In medication-overuse headache, fMRI shows long-lasting dysfunction in midbrain areas. Headache (2012) 0.91
A radial glia gene marker, fatty acid binding protein 7 (FABP7), is involved in proliferation and invasion of glioblastoma cells. PLoS One (2012) 0.91
DNA damage in mammalian neural stem cells leads to astrocytic differentiation mediated by BMP2 signaling through JAK-STAT. Stem Cell Reports (2013) 0.91
Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. Ann Neurol (2002) 0.91
Histological variants of medulloblastoma are the most powerful clinical prognostic indicators. Pediatr Blood Cancer (2012) 0.90
FOXP3, a novel glioblastoma oncosuppressor, affects proliferation and migration. Oncotarget (2012) 0.90
Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. PLoS One (2013) 0.89
Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis. Int J Cancer (2003) 0.89
A case of pediatric tumefactive demyelinating lesion misdiagnosed and treated as glioblastoma. J Child Neurol (2008) 0.89
Identification of Myb-binding protein 1A (MYBBP1A) as a novel substrate for aurora B kinase. J Biol Chem (2010) 0.89
A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment. Cancer Immunol Immunother (2011) 0.89
Reelin affects chain-migration and differentiation of neural precursor cells. Mol Cell Neurosci (2009) 0.89
Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature. Neurosurg Rev (2015) 0.89